Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 6:2015:1-10.

Neuroimaging Biomarkers for Psychosis

Brandon M Hager  1 , Matcheri S Keshavan  2
Affiliations

Neuroimaging Biomarkers for Psychosis

Brandon M Hager et al. Curr Behav Neurosci Rep. .

Abstract

Background: Biomarkers provide clinicians with a predictable model for the diagnosis, treatment and follow-up of medical ailments. Psychiatry has lagged behind other areas of medicine in the identification of biomarkers for clinical diagnosis and treatment. In this review, we investigated the current state of neuroimaging as it pertains to biomarkers for psychosis.

Methods: We reviewed systematic reviews and meta-analyses of the structural (sMRI), functional (fMRI), diffusion-tensor (DTI), Positron emission tomography (PET) and spectroscopy (MRS) studies of subjects at-risk or those with an established schizophrenic illness. Only articles reporting effect-sizes and confidence intervals were included in an assessment of robustness.

Results: Out of the identified meta-analyses and systematic reviews, 21 studies met the inclusion criteria for assessment. There were 13 sMRI, 4 PET, 3 MRS, and 1 DTI studies. The search terms included in the current review encompassed familial high risk (FHR), clinical high risk (CHR), First episode (FES), Chronic (CSZ), schizophrenia spectrum disorders (SSD), and healthy controls (HC).

Conclusions: Currently, few neuroimaging biomarkers can be considered ready for diagnostic use in patients with psychosis. At least in part, this may be related to the challenges inherent in the current symptom-based approach to classifying these disorders. While available studies suggest a possible value of imaging biomarkers for monitoring disease progression, more systematic research is needed. To date, the best value of imaging data in psychoses has been to shed light on questions of disease pathophysiology, especially through the characterization of endophenotypes.

Keywords: MRS; PET; fMRI; neuroimaging biomarkers; psychosissMRI.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Brandon Hager and Matcheri Keshavan have no relevant disclosures.

References

    1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95. - PubMed
    1. Prata D, Mechelli A, Kapur S. Clinically meaningful biomarkers for psychosis: a systematic and quantitative review. Neurosci Biobehav Rev. 2014;45:134–41. A systematic look at the value of biomarkers for clinical psychiatry. The results are sobering, with only one biomarker possibly meeting the stringent criteria for a clinically useful biomarker. - PubMed
    1. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. Schizophrenia, “just the facts”: what we know in 2008 Part 3: neurobiology. Schizophr Res. 2008;106(2–3):89–107. - PubMed
    1. Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. 2008 Available from: http://www.cochrane-handbook.org/
    1. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biological Reviews Cambridge Philosophical Society. 2007;82(4):591–605. - PubMed